Female libido problems ‘exaggerated’ to line the pockets of drug companies?
The Guardian reports on claims made by academic Ray Moynihan in the British Medical Journal today, suggesting that drug companies are guilty of misrepresenting issues of female libido for their own benefit.
Moynihan, an academic at Newcastle University in Australia, argues that the pharmaceutical companies have exaggerated the extent of the problem of low sexual desire in women, and medicalised the treatment of what may well be largely a psychosocial problem, in order to create a market for pills.
In particular, he questions a survey conducted by Pfizer, (the company who make Viagra) that concluded up to a third of European women lack interest in sex, and that Viagra could be useful in the treatment of this condition, despite the fact that drugs have failed to work well in many cases and the figures for women affected fail to hold up to scrutiny.
It’s a tricky one this. There is no doubt that the pharmaceutical companies are out to sell their product, and it is particularly worrying that Moynihan also references cases in the US of them funding education for doctors, in which drugs are again offered as a simple solution to these complex problems.
But as Dr Sandy Goldbeck-Wood, a specialist in psycho-sexual medicine points out, lack of sex drive and other sexual difficulties can make women profoundly unhappy, and to dismiss their problems as rare or unimportant is potentially as bad as wrongly treating them.
Perhaps the key is to listen to women themselves then and not to leave those who need it without help. As Dr Goldbeck-Wood puts it:
“Many factors can contribute to low libido, few of them treatable with drugs.We owe these women something more respectful than ineffective medication or patronising false reassurance.”











